All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
In Acute Myeloid Leukemia (AML), the Programmed Death-1 (PD-1) pathway is hijacked by leukemic cells to facilitate immune evasion which can lead to poor outcomes in patients. AML cells upregulate their expression of Programmed Death Ligand 1 and 2 (PD-L1/PD-L2) thus leading to an inhibition of effector T-cell function via the PD-1 pathway. There is a paucity of data on the epigenetic regulation of PD-1/PD-L1 axis and the mechanism of promoter methylation of PD-L1 (CD274) and PD-L2 in AML has not been elucidated yet.
In a Letter to the Editor of Leukemia, Diane Goltz and colleagues from the University Hospital Bonn, Germany, investigated whether there is any association between PD-L1/PD-L2 mRNA expression in AML and promoter methylation (mPD-L1/mPD-L2).
In this study, gene methylation and mRNA data were obtained from AML patient (n =197) diagnostic samples generated by the TCGA Research Network.
In summary, promoter methylation of PD-L1 can predict the survival outcomes of AML patients. The authors concluded by suggesting that PD-L1 methylation should be “considered as a companion biomarker” and should be analyzed in current clinical trials with PD-L1/PD-1 blockage in AML patients.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox